相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Synthesis and in Vitro and in Vivo Biological Evaluation of Tissue-Specific Bisthiazole Histone Deacetylase (HDAC) Inhibitors
Shu-Wei Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Clinical management of third-generation EGFR inhibitor-resistant patients with advanced non-small cell lung cancer: Current status and future perspectives
Yi-Chen Zhang et al.
CANCER LETTERS (2019)
Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer
Azusa Tanimoto et al.
CLINICAL CANCER RESEARCH (2017)
Epigenetic plasticity and the hallmarks of cancer
William A. Flavahan et al.
SCIENCE (2017)
Nuclear Met promotes hepatocellular carcinoma tumorigenesis and metastasis by upregulation of TAK1 and activation of NF-κB pathway
Sze Keong Tey et al.
CANCER LETTERS (2017)
Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo
Weiwei Yu et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells
Shao Xie et al.
ACTA PHARMACOLOGICA SINICA (2016)
Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia
Elena Ceccacci et al.
BRITISH JOURNAL OF CANCER (2016)
HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma
Zhihao Wang et al.
ONCOLOGY REPORTS (2016)
Panobinostat for the Treatment of Multiple Myeloma
Jacob P. Laubach et al.
CLINICAL CANCER RESEARCH (2015)
HDAC inhibitors: a new radiosensitizer for non-small-cell lung cancer
Lucheng Zhu et al.
TUMORI (2015)
HDAC inhibitors: a new radiosensitizer for non-small-cell lung cancer
Lucheng Zhu et al.
TUMORI (2015)
Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer
Xian Li et al.
CANCER LETTERS (2014)
A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors
Jhanelle E. Gray et al.
CLINICAL CANCER RESEARCH (2014)
Histones and lung cancer: are the histone deacetylases a promising therapeutic target?
Vasiliki Petta et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC Inhibition
Takayuki Nakagawa et al.
CANCER RESEARCH (2013)
Beyond NF-κB activation: nuclear functions of IκB kinase α
Wei-Chien Huang et al.
JOURNAL OF BIOMEDICAL SCIENCE (2013)
Panobinostat for the treatment of multiple myeloma
Paola Neri et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
MET: a promising anticancer therapeutic target
Solange Peters et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
The Met Protooncogene Is a Transcriptional Target of NFkappaB: Implications for Cell Survival
James Y. Dai et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2009)
Vorinostat (NSC# 701852) in Patients with Relapsed Non-small Cell Lung Cancer A Wisconsin Oncology Network Phase II Study
Anne M. Traynor et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors
Michalis V. Karamouzis et al.
LANCET ONCOLOGY (2009)
Drug therapy: EGFR antagonists in cancer treatment
Fortunato Ciardiello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells
Arthur Edwards et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Promoter-dependent effect of IKKα on NF-κB/p65 DNA binding
Geoffrey Gloire et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
IKKα limits macrophage NF-κB activation and contributes to the resolution of inflammation
T Lawrence et al.
NATURE (2005)
Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase
F Yeung et al.
EMBO JOURNAL (2004)
Potentiation of tumor necrosis factor-induced NF-κB activation by deacetylase inhibitors is associated with a delayed cytoplasmic reappearance of IκBα
E Adam et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
Histone H3 phosphorylation by IKK-α is critical for cytokine-induced gene expression
Y Yamamoto et al.
NATURE (2003)
Acetylation of ReIA at discrete sites regulates distinct nuclear functions of NF-κB
LF Chen et al.
EMBO JOURNAL (2002)
The p65 (RelA) subunit of NF-κB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression
BP Ashburner et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Duration of nuclear NF-κB action regulated by reversible acetylation
LF Chen et al.
SCIENCE (2001)
分享论文
